Xtant Medical (NYSEAMERICAN:XTNT) Announces Earnings Results, Hits Expectations

Xtant Medical (NYSEAMERICAN:XTNT) posted its quarterly earnings results on Wednesday. The medical device company reported ($0.02) EPS for the quarter, meeting the consensus estimate of ($0.02), FiscalAI reports. Xtant Medical had a net margin of 3.71% and a return on equity of 10.27%. The firm had revenue of $20.88 million for the quarter, compared to analyst estimates of $20.16 million.

Here are the key takeaways from Xtant Medical’s conference call:

• Xtant raised its full-year 2026 revenue guidance to $101 million to $105 million, citing the addition of HEMOBLAST, recent product launches, and expanded sales coverage.
• The company secured exclusive U.S. distribution rights to HEMOBLAST Bellows, giving it entry into an estimated $2 billion hemostatic products market and broadening its biologics portfolio.
• Proceeds from the Companion Spine divestiture were used to strengthen the balance sheet, with Xtant reducing total indebtedness by $13.3 million in the quarter and increasing revolver availability.
• First-quarter revenue was $20.9 million, down from the prior-year period on a pro forma basis, mainly due to headwinds in amnio products tied to the advanced wound care market and the loss of non-recurring license revenue.
• Gross margin fell to 57.3% from 61.5% last year, and the company said the decline reflected the end of Q-code license revenue plus some product-mix pressure and excess inventory charges.

Xtant Medical Stock Down 4.8%

Shares of NYSEAMERICAN XTNT traded down $0.02 during trading on Wednesday, reaching $0.48. 301,934 shares of the stock were exchanged, compared to its average volume of 159,301. The business’s 50-day moving average price is $0.55 and its 200 day moving average price is $0.64. Xtant Medical has a twelve month low of $0.44 and a twelve month high of $0.95. The company has a quick ratio of 1.63, a current ratio of 2.65 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $67.23 million, a price-to-earnings ratio of 16.01 and a beta of -0.11.

Hedge Funds Weigh In On Xtant Medical

A number of institutional investors have recently added to or reduced their stakes in XTNT. Wiregrass Investment Management LLC acquired a new stake in shares of Xtant Medical during the fourth quarter valued at about $81,000. Renaissance Technologies LLC boosted its holdings in Xtant Medical by 28.8% in the fourth quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock valued at $721,000 after purchasing an additional 205,945 shares during the last quarter. Vanguard Group Inc. grew its stake in Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after purchasing an additional 104,159 shares in the last quarter. Mink Brook Asset Management LLC increased its holdings in Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after purchasing an additional 60,997 shares during the last quarter. Finally, Nantahala Capital Management LLC increased its holdings in Xtant Medical by 500.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock worth $50,543,000 after purchasing an additional 57,000,000 shares during the last quarter. Institutional investors and hedge funds own 69.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on XTNT shares. Craig Hallum restated a “buy” rating on shares of Xtant Medical in a report on Wednesday, March 18th. BTIG Research reiterated a “buy” rating and issued a $1.00 price target on shares of Xtant Medical in a report on Wednesday. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $1.00.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.